Paul Feuerstadt, MD, FACG, AGAF, discusses how testing for Clostridioides difficile is recommended for hospitalized patients or outpatients with new-onset, unexplained diarrhea who have risk factors ...

The researchers wrote that their findings showcase the need for close monitoring of patients and for effective treatments for those with recurrent infection, which occurs in 15%-30% of all patients ...

A new study from the University of Birmingham has shown that fecal microbiota transplants (FMT) are highly successful in treating patients with Clostridioides difficile (C. diff) infection. A new ...

Fecal transplant treatment for patients with recurrent Clostridioides difficile is more effective and more likely to prevent bloodstream infections than antibiotics, according to a study published Nov ...

A fecal transplant performs as well as antibiotics in treating people with a bacterial infection that can cause life-threatening diarrhea, a new study says. People who received a single fecal ...

Researchers from North Carolina State University have found that a commonly used drug made from secondary bile acids can affect the life cycle of Clostridioides difficile (C. diff) in vitro and reduce ...

In a new Annals "Beyond the Guidelines" feature, an infectious diseases specialist and a gastroenterologist discuss the benefits and risks of different treatment approaches for Clostridioides ...

Please provide your email address to receive an email when new articles are posted on . New guidelines issued in 2021 stated a preference for fidaxomicin as first-line treatment for Clostridioides ...

Clostridium bacteria, computer illustration. Clostridia are spore-forming bacteria that include several human pathogenic species, C. difficile, C. tetani, C. botulinum, C. perfringens, and others. C.

Fecal microbiota transplantation has become one of the most effective treatments for recurrent Clostridioides difficile infections, but its long-term role in gastroenterology may hinge on moving ...

NEW YORK CITY, NY / ACCESS Newswire / May 19, 2026 / New to The Street's longtime featured biotechnology client, Acurx ...